Effects of Mirtogenol® on ocular blood flow and intraocular hypertension in asymptomatic subjects by Steigerwalt, Robert D. et al.
Effects of Mirtogenol
® on ocular blood flow and intraocular
hypertension in asymptomatic subjects
Robert D. Steigerwalt Jr.,1 Belcaro Gianni,1 Morazzoni Paolo,2 Ezio Bombardelli,2 Carolina Burki,3 Frank
Schönlau4
1Department of Biomedical Sciences, University of Chieti-Pescara, San Valentino, Italy; 2Indena S.p.A. Scientific Department,
Milan, Italy; 3Horphag Research (UK) Ltd., Geneva, Switzerland; 4Horphag Research (UK) Ltd., London, United Kingdom
Purpose: The most important variable risk factor for developing glaucoma is intraocular hypertension. Timely lowering
of high intraocular pressure (IOP) significantly lowers the likelihood of developing glaucoma. The aim of this study was
to evaluate the effects of the food supplement Mirtogenol® (Mirtoselect® and Pycnogenol®) on IOP and ocular blood flow
in a product evaluation study.
Methods: Thirty-eight asymptomatic subjects with intraocular hypertension were either given Mirtogenol® (20 subjects)
or were not treated (18 subjects). The visual acuity, IOP, and ocular blood flow were measured at two, three, and six
months.
Results: After two months of supplementation with Mirtogenol®, the mean IOP decreased from a baseline of 25.2 mmHg
to 22.2 mmHg. After three months of treatment with Mirtogenol®, the IOP was significantly lowered compared to that of
untreated controls (p<0.05) to 22.0 mmHg. No further improvement was found after six months. Nineteen of the twenty
patients taking Mirtogenol had a decreased IOP after three months. Only marginal effects on the IOP were found in the
18 control subjects. No side effects were observed. Ocular blood flow (central retinal, ophthalmic, and posterior ciliary
arteries) improved both in the systolic and diastolic components as measured by Color Doppler imaging. After three
months of treatment, the improvement of ocular blood flow was significant as compared to both baseline and control
group (p<0.05).
Conclusions: An improved ocular blood flow may contribute to the prevention of glaucoma. The results of this study
indicate that Mirtogenol® may represent a safe preventative intervention for lowering the risk for developing symptomatic
glaucoma by controlling IOP and improving ocular blood flow.
The age-related decline of vision is caused by physiologic
and pathologic degenerative processes. There are four major
causes  for  age-related  visual  loss:  cataract,  age-related
macular  degeneration  (AMD),  retinopathy,  and  glaucoma
[1]. Due to the possibility of surgery for cataracts, AMD is
now the leading cause of blindness in developed countries.
With the global diabetes epidemic, retinopathy is expected to
represent a growing problem in the future. The second leading
cause for blindness is glaucoma of which different forms exist
with  a  progressive  optic  neuropathy  as  the  common
denominator. Primary open-angle glaucoma (POAG) is one
of the most common forms of glaucoma [2].
Except for cataract, there is no real treatment available
for AMD, retinopathy, and POAG. Slowing of the progression
of these diseases remains the only resort. With the aging of
the  population,  prevention  of  eye  diseases  receives
considerable  attention.  Nutritional  intervention,
predominantly with antioxidants, has been suggested to lower
the incidence of degenerative eye disorders. A study of 35,551
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female health professionals over a period of 10 years has
found a significant risk reduction for developing cataract with
a higher dietary intake of lutein/zeaxanthin and vitamin E
from food or dietary supplements [3]. Epidemiologic studies
have clearly demonstrated that dietary vitamin C and E as well
as zinc and the carotenoids, lutein and zeaxanthin, have a
protective effect in AMD and may slow disease progression
[4]. Protection from developing AMD is also suggested from
dietary omega-3 fatty acids [5]. For diabetic retinopathy, the
best risk reduction is a tight blood glucose control [6]. Specific
flavonoids  such  as  the  standardized  bilberry  extract,
Mirtoselect,  and  the  French  maritime  pine  bark  extract,
Pycnogenol, have been successfully tested for counteracting
progression of retinopathy [7-9].
An effective dietary prevention for reduced progression
of POAG has so far not been identified. The relation between
dietary antioxidant intake and risk of POAG was examined in
participants over 40 years of age in the Nurse’s Health Study
(n=76,200) and the Health Professionals Follow-up Study
(n=40,284)  [10].  No  significant  association  between
antioxidant  consumption  (vitamin  A,  C,  E,  β-carotene,  β-
cryptoxanthin, lycopene, lutein, and zeaxanthin) and the risk
for  developing  POAG  was  found.  Only  recently  an
investigation  of  1,155  women  with  osteoporotic  fractures
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1288proposed that a higher intake of certain fruits and vegetables
may be associated with a decreased risk of glaucoma [11]. The
Ocular Hypertension Treatment Study (OHTS), initiated by
the US National Institute of Health, has clearly shown that the
lowering of intraocular pressure (IOP) is the one variable
factor able to decrease the risk for developing POAG. Topical
ocular hypotensive medication was effective in significantly
delaying or preventing the onset of POAG in individuals with
elevated IOP [12].
Specific flavonoids that are well studied for improving
micro-vascular functions may also exert beneficial effects on
IOP.  The  effect  of  a  proprietary  flavonoid  composition,
Mirtogenol® (registered trademark of Indena, Milan, Italy and
Horphag Research, London, UK), in subjects with an elevated
IOP without glaucoma and with normal vision was studied in
a six month trial.
METHODS
Thirty-eight  subjects  were  studied  and  divided  into  two
groups. The Mirtogenol® group, consisting of 20 subjects aged
44.8±6.5 years (12 males and 8 females), were treated with
Mirtogenol®. The control group, consisting of 18 subjects
aged 44.7±9.2 years (9 males and 9 females), were followed
up without treatment. All subjects had complete eye exams,
ocular hypertension, and no signs of glaucoma. Their IOP
ranged from 22 mmHg to 26 mmHg, and they were not under
treatment for the elevated IOP. They all had a cup to disk ratio
of less than 0.5, a central corneal thickness greater than 555
microns, and no visual field defects. Subjects with existing
POAG or other degenerative eye disorders were excluded.
Subjects  with  cardiovascular  diseases  requiring  medical
intervention and those who had any surgery, radiotherapy, or
chemotherapy in the last three months were also excluded.
Subjects  who  were  pregnant,  breast  feeding,  or  planning
conception  were  excluded  as  well.  All  the  subjects  were
informed about the aim of the study and treatment procedure
according to the Declaration of Helsinki and gave their written
informed consent for participation in this investigation. An
approval by the ethics committee was not required for this
investigation as the subjects were healthy with moderately
elevated IOP. The subjects were allowed to take multi-vitamin
tablets and any other kind of supplements without restriction.
The  patients  in  the  treatment  group  were  given
Mirtogenol®, one in the morning (AM) and one in the evening
(PM),  for  six  months.  The  Mirtogenol®  tablets  contained
40 mg of French maritime pine bark extract, Pycnogenol®
(Horphag  Research,  London,  UK),  and  80  mg  of
Mirtoselect®  standardized  bilberry  extract  (Indena,  Milan,
Italy). In total, the daily dosage was 80 mg of Pycnogenol®
and 160 mg of Mirtoselect®. The control group remained
untreated.  The  IOP  was  measured  with  the  standard
Goldmann applanation tonometer at the same time in the
morning.  Measurements  were  all  performed  by  the  same
person to rule out any variations from one investigator to
another. At each visit, the IOP was measured in triplicate and
mean values were recorded. Visual acuity was obtained using
the Snellen chart. Color Doppler imaging (CDI) was used to
measure the peak systolic flow velocity (PSFV) and the end
diastolic flow velocity (EDFV) of the ophthalmic artery (OA),
central retinal artery (CRA), and the posterior ciliary artery
(PCA) as previously described [13].
Non-parametric statistics (Mann–Whitney U-test) were
used to evaluate the data since the distribution of the IOP and
the ocular blood flow were not normal and no standard data
was available for these patients. A group of at least 15 subjects
in  each  group  was  considered  a  minimal  requirement  for
evaluating  variations  in  the  IOP  and  ocular  blood  flow,
overcoming individual variations, and detecting at least a 5%
variation in the evaluated item.
RESULTS
The Mirtogenol® group (20 subjects) and the control group
(18 subjects) were comparable for age (44.8±6.5 years versus
44.7±9.2 years, respectively) and male to female ratio (12:8
versus 9:9, respectively).
The baseline IOP and standard deviation in the treatment
(Mirtogenol®) group (25.2±3.1 mmHg) was comparable to the
IOP  in  the  controls  (24.6±2.8  mmHg).  Evaluation
measurements were made at two months. A decrease in IOP
to 22.2±2.1 mmHg in the Mirtogenol® group was observed.
Only a minor decrease to 24.0±2.2 mmHg was found in the
controls.  The  IOP  after  three  months  of  treatment  with
Mirtogenol® was 22.0±2.6 mmHg, which was statistically
significantly less than at baseline as well as significantly less
than the value of 24.5±2.3 mmHg in the controls (p<0.05).
Another measurement of IOP was performed after six months,
which  did  not  indicate  a  further  lowering  of  IOP  in  the
Mirtogenol® group (22.0 mmHg ± 2.3) and showed no effect
in  controls  (24.7±2.2  mmHg;  Figure  1).  Nineteen  out  of
twenty patients in the Mirtogenol® group showed a reduced
IOP whereas only 1 of the 18 patients in the control group
showed  a  lowered  IOP  after  the  six-month  investigation
period. During the course of the study, none of the patients in
either  group  had  an  increased  IOP,  which  would  have
prompted immediate termination of the patient’s participation
in the trial. The visual acuity was normal at trial start and
stayed normal in both groups (data not shown).
CDI was obtained from the patient’s ophthalmic, central
retinal, and posterior ciliary arteries. The baseline maximum
flow velocity (systolic component) was defined at inclusion
as  100%  for  comparison  with  flow  velocities  obtained  in
response  to  treatment.  As  presented  in  Table  1,  both  the
systolic and diastolic components of all three ocular arteries
improved (increased), reaching significance after three and six
months (p<0.05). This finding suggests an improved ocular
arterial blood flow and consequently better tissue oxygenation
with Mirtogenol®. No significant changes of ocular blood flow
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(data not shown). None of the subjects reported side effects,
and drop outs did not occur during the trial.
DISCUSSION
Our objective was to identify a suitable intervention with the
potential for protection against developing glaucoma. The
major  variable  risk  factor  for  developing  glaucoma  is  an
elevated IOP; therefore, this parameter was singled out as a
suitable target for improvement by nutritional means. IOP is
regulated by the balance between the secretion and drainage
of aqueous humor. The biomechanical parameters and fluid
hydrodynamics of the aqueous outflow pathways are complex
and not fully  understood  [14].  This  is  due  to the technical
challenges of the unique ocular anatomy with minute amounts
of tissue available for study and the difficulties in studying
these tissues in vivo. The exact site and nature of a resistance
of the outflow system is uncertain.
Many classes of drugs are currently used for lowering
IOP in patients with POAG. Mostly applied as eye drops they
may reduce the production of aqueous such as in the case of
Figure 1. The development of intraocular pressure in subjects treated
with  Mirtogenol®.  The  asterisk  indicates  statistical  significant
difference to the baseline as well as control (p<0.05).
beta  blockers,  alpha-adrenergic  agents,  and  carbonic
anhydrase inhibitors. The widely used prostaglandin analogs
(e.g., “latanoprost”) increase uveoscleral outflow probably by
rendering capillaries more absorptive as a result of stimulated
matrix  metalloproteinase  secretion.  Inflammatory
manifestations in human conjunctiva were described for the
long-term use of prostaglandin analogs [15]. Interestingly, the
exact method of action of the commonly applied beta-blocker,
timolol,  remains  unknown.  Timolol  appears  to  not
significantly alter the blood aqueous barrier as shown with
fluorescence  angiography  [16].  Essentially,  all  these  eye
drops  for  intraocular  hypertension  are  known  to  cause
considerable local and systemic side effects [17].
We  speculate  that  a  vascular  function  could  play  a
significant role in the pathomechanisms underlying high IOP.
There  are  observations  suggesting  an  involvement  of  an
impaired vascular response for an increased IOP [18]. The
well known increase of IOP in the supine position is more
pronounced and develops faster in aging healthy people than
in  young  healthy  people,  suggesting  less  resistance  to
hydrostatic pressure with older age [19]. This is expected to
result from an increased aqueous release from the ciliary body.
Pharmacologic  studies  have  previously  described  that
Mirtoselect®  counteracts  the  hyperpermeability  of  ciliary
capillaries,  initiated  by  paracentesis,  as  measured  by  the
Evans  Blue  concentration  in  the  aqueous  humor  [20].
Furthermore,  as  recently  reviewed,  anthocyanosides
contained in the standardized bilberry extract are the only
flavonoids  able  to  reach  the  eye  as  a  target  organ  in
experimental  animals.  Unchanged  anthocyanosides
demonstrated after oral administration that it is absorbed and
distributed  into  ocular  tissues,  showing  its  ability  to  pass
through the blood-aqueous and blood retinal barriers [21].
Mirtoselect® as a consequence has been suggested to be
useful as a therapeutic application for ophthalmic problems
involving the altered blood-aqueous barriers [22].
TABLE 1. COLOR DOPPLER VELOCITY MEASUREMENTS OF OCULAR ARTERIES IN RESPONSE TO MIRTOGENOL®.
Baseline 2 months 3 months 6 months
compared to baseline
Central retinal artery systolic 100% +13% +21% +20%
diastolic 23% +34% +39% +38%
Ophthalmic artery systolic 100% +22% +22% +23%
diastolic 15% +19% +25% +25%
Posterior ciliaryartery systolic 100% +22% +21% +22%
diastolic 14% +24% +24% +23%
The mean systolic component of subjects at the baseline before treatment is set to 100% for comparison with the diastolic
component as well as subsequent systolic values found after two, three, and six months of treatment with Mirtogenol® . The
increased arterial flow velocity was statistically significant after three and six months compared to the baseline as well as the
control group values (p<0.05). In the case of controls, no alterations of flow velocity were found (data not shown).
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a significant reduction of retinal micro-hemorrhages, and a
regression of localized retinal edema was found using fundus
fluorescence angiography [23]. The effect of bilberry extract
on  the  ocular  micro-circulation  was  investigated  in
exploratory studies using electroretinography in patients with
myopia and glaucoma [24]. Pycnogenol® likewise was shown
to improve pathologic permeability of blood vessels [25] and
has  been  extensively  studied  for  enhancing  capillary
resistance and integrity in retinopathy [9].
There is increasing evidence of the contractile activities
of  the  trabecular  meshwork,  which  allows  for  regulatory
mechanisms controlling fluid outflow. Trabecular meshwork
cells exhibit smooth muscle-like contractile properties, which
respond to the vasoconstrictory peptide, endothelin-1 [26].
Endothelin-1 has been identified in elevated quantities in the
aqueous humor of patients with POAG. Furthermore, there is
experimental  evidence  for  endothelial  nitric  oxide  being
involved in the regulation of ocular vascular tone. In healthy
volunteers,  infusion  of  nitric  synthase  inhibitor  N-
monomethyl-L-arginine  (L-NMMA)  significantly  reduced
pulsatile  choroidal  and  total  choroidal  blood  flow  [27].
Pycnogenol®  has  previously  been  shown  to  significantly
enhance the generation of endothelial nitric oxide in healthy
humans  [28].  Pycnogenol®  has  also  been  found  to
significantly lower plasma endothelin-1 in patients with type
II diabetes [29]. Mirtoselect® bilberry extract was found to
stimulate arteriolar vasomotion in preclinical tests [30]. In our
study, we were indeed able to demonstrate an improved blood
flow velocity of patient’s ophthalmic artery, central retinal
artery, and posterior ciliary arteries with Mirtogenol®.
It  is  not  known  whether  Mirtogenol®  affects  outflow
pathways or aqueous humor inflow or both. This will remain
very difficult to identify. Methods such as the “water-drinking
test,” which involves a significant IOP increase subsequent to
drinking large quantities of water, might offer some insight.
It  was  suggested  that  medications,  which  predominantly
enhance outflow such as prostaglandin analogs, provide better
IOP stabilization in such experiments [31].
Our study is the first demonstration showing that dietary
intervention can help to control IOP and increase ocular blood
flow  in  asymptomatic  subjects  and  if  taken  in  time,  may
prevent  an  evolution  to  higher  pressure  and  symptomatic
glaucoma.  The  safety  of  Mirtogenol  is  warranted  as  its
components Mirtoselect and Pycnogenol are used as dietary
supplements since decades without serious side effects. A
clinical trial with a larger number of subjects should further
assess the benefits of Mirtogenol for controlling IOP.
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